Idexx Laboratories Receivables

Idexx Laboratories (IDXX) currently reports a receivables of $630M as of June 2026. That compares with $660M in the prior-year period — down 5.5% year over year. Use the charts on this page to explore Idexx Laboratories's receivables history and peer comparisons.

Idexx Laboratories's receivables decreased from $660M to $630M — a 5.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Idexx Laboratories reported $630M in receivables as of June 2026. That compares with $660M in the prior-year period — down 5.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $630M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Idexx Laboratories, and consider following IDXX for alerts when major investors trade the stock.

Idexx Laboratories is classified in the Healthcare sector. On receivables, it currently shows $630M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IDXX with unrelated industries.